Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis

JOURNAL ARTICLE published November 2021 in The Lancet Oncology

Authors: Jennifer J Gao | Joyce Cheng | Tatiana M Prowell | Erik Bloomquist | Shenghui Tang | Suparna B Wedam | Melanie Royce | Danielle Krol | Christy Osgood | Gwynn Ison | Rajeshwari Sridhara | Richard Pazdur | Julia A Beaver | Laleh Amiri-Kordestani